中文 | English

Oncology anti-PD1-antibody combination therapies for advanced solid tumors, is it the next blockbuster?

Event details

DATE
Wednesday Jul 28th, 2021

VENUE
Online Webex / Zoom

TIME
10:00 – 11:00 Berlin time (CET)
16:00 - 17:00 Beijing time (GMT+8)

RSVP
This is a complimentary event
VIP tickets priority for Lingmed current clients
Please RSVP by Jul 27th, 2021
PRESENTERS
Lingling Cao, CEO & Founder
Dr Hank Wang, Medical advisor
Guest speaker

REGISTER
+86 21 5386 3003
BD@lingmed.net

Agenda

CET 10:00 - 10:30 – Updates in mono and combination anti-PD1-antibody therapies
– Global & China launched and pipeline anti-PD1-antibodies for cancer
by Dr Hank Wang  (Chinese)
CET 10:30 - 10:35Linkedbio services & projects introductions    by Lingling Cao  (English)
CET 10:35 - 10:55Roadshow of innovative anti-PD1-antibody combination therapies asset by Guest speaker   (English)
CET 10:55 – 11:00Q&A (English & Chinese)

Presenters

Hank Wang
Medical advisor
Dr Wang holds a PhD degree on Medicinal Chemistry from Peking University, has a Postdoc experience in University of Missouri-Saint Louis, and worked as a Postdoc Fellow in Auburn University. Hank Wang has more than 10 years’ experience in pharmaceuticals industry. Hank has worked as Vice President and President of R&D at Beijing Haiyan Pharmaceutical Co., Ltd. - Yangtze River Pharmaceutical Group. Dr Wang advises Lingmed on innovative assets evaluation for China market

Lingling Cao
CEO & Founder
Lingling has more than a decade of experience in the healthcare industry, especially in deal-making. She founded Lingmed, which aims to support BD professionals to make better decisions with intelligence databases and EU-China cross-border deals. Prior to her venture at Lingmed, she was a senior BD manager for Eli Lilly in Shanghai and a consultant for McKinsey in Germany

Download meeting reports
©Copyright 2013 - 2021 Lingmed Limited